Sign In
Buy BEAM
$35.53
+1.39 (+4.07%)
At Close: Jun 22, 2026
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria
11:36am, Friday, 19'th Jun 2026
Beam Therapeutics gains after the FDA clears the IND for BEAM-304 in PKU, advancing its liver-targeted gene-editing program into clinical testing.
BEAM-304 Development Approach Has Potential to Create Transformative, One-time Therapies for the Majority of Patients with PKU BEAM-304 Program Designed as Platform-based Approach Reflecting Emergin
The Healthcare M&A Wave
12:30pm, Wednesday, 17'th Jun 2026
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Beam Therapeutics Stock Soars 21% in Three Months: Here's Why
09:51am, Tuesday, 16'th Jun 2026
BEAM shares jump 21% in three months as promising BEAM-302 data, pipeline milestones and a cash runway into mid-2029 boost investor confidence.
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
01:10pm, Tuesday, 02'nd Jun 2026
Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.
Beam Therapeutics Inc. (BEAM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
01:37pm, Monday, 25'th May 2026
Beam Therapeutics Inc. (BEAM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances
02:05pm, Wednesday, 20'th May 2026
Beam Therapeutics NASDAQ: BEAM Chief Executive Officer John Evans said the company is advancing its base-editing platform across hematology and liver disease programs, with a potential biologics licen
Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including Detailed Safety Results, Efficacy Durability and Reduction in Human Neutrophil Elastase Activity Po
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?
02:05pm, Monday, 18'th May 2026
Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
12:00pm, Wednesday, 13'th May 2026
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 PR Newswire DURHAM, N.C., May 13, 2026
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
11:49am, Wednesday, 13'th May 2026
The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease. DURHAM, N.C.
Beam Therapeutics: Base Editing Is Moving From Platform Story To Regulatory Asset Story
09:46am, Wednesday, 13'th May 2026
Beam Therapeutics is transitioning from a scientific platform to a late-stage genetic medicine company with a clear commercial bridge. BEAM's $1.2B cash position supports a runway into mid-2029, enabl
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
07:00am, Wednesday, 13'th May 2026
CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John
CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the
BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates
01:11pm, Friday, 08'th May 2026
Beam Therapeutics Q1 revenues beat estimates as its gene-editing pipeline advanced, with key updates across the SCD, AATD and PKU programs.
